Harisitha P
Department of Pharmacy Practice, Siddhartha College of Pharmaceutical Sciences, IndiaPublications
-
Research Article
Structure Based Virtual Screening of Selected Phytochemicals aganist C1156y Mutant Anaplastic Lymphoma Kinase (ALK) using Molecular Docking and Admet Prediction
Author(s): Kanaka Durga Devi N*, Bharghava Bhushan Rao P, Ramya B, Sireesha U, Chandana M, Bhavana K, Likitha N, Harisitha P and Ravi Sankar K
Lung cancer is one of the fatal malignancies in both men and women worldwide. Anaplastic Lymphoma Kinase (ALK) rearrangements triggered the fusion of echinoderm microtubule-associated protein-like 4 (EML4) and ALK increasing the tyrosine kinase activity leading to cell proliferation and tumourigenesis causing Non-Small Cell Lung Cancer (NSCLC). Crizotinib emerged as a first-generation ALK inhibitor; however it developed resistance within a year of initiation of treatment in a few patients with deteriorating therapeutic outcomes. Various secondary mutations in ALK are responsible for crizotinib resistance in patients. C1156Y is a point mutation seen in patients resistant to crizotinib. Although second and third-generation ALK inhibitors are currently available, there is still a need to develop new ALK inhibitors as the existing compounds are developing resistance. In this study, we screen.. Read More»
DOI: 10.4303/jdar/236156